After 2% DSS treatment for 7 days, Trpv1G564S+/+ > WT chimeras had colitis development similar to that of Trpv1G564S+/+ > Trpv1G564S+/+ chimeras in terms of body weight loss (Figure 1F) and histological inflammation score (Figure 1G), suggesting that colonic epithelial cells were not the primary targets for TRPV1 gain of function to confer enhanced susceptibility to colitis. The gene discussed is TRPV1; the disease is colitis.